Therefore, survivin expression appears to predict the clinical course of RA [16]; whereas, anti-survivin antibodies (a proxy for the anti-survivin immune response) are associated with less severe disease [13]. This evidence concerns the gene BIRC5 and rheumatoid arthritis.